21.10
+0.88(+4.35%)
Currency In USD
| Previous Close | 20.22 |
| Open | 20.11 |
| Day High | 21.2 |
| Day Low | 20.06 |
| 52-Week High | 21.56 |
| 52-Week Low | 5.12 |
| Volume | 897,115 |
| Average Volume | 1.28M |
| Market Cap | 1.84B |
| PE | -4.67 |
| EPS | -4.52 |
| Moving Average 50 Days | 18.64 |
| Moving Average 200 Days | 12.74 |
| Change | 0.88 |
If you invested $1000 in Travere Therapeutics, Inc. (TVTX) 10 years ago, it would be worth $1,582.9 as of February 05, 2025 at a share price of $21.1. Whereas If you bought $1000 worth of Travere Therapeutics, Inc. (TVTX) shares 5 years ago, it would be worth $1,249.26 as of February 05, 2025 at a share price of $21.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Travere Therapeutics Provides Corporate Update and 2025 Outlook
GlobeNewswire Inc.
Jan 13, 2025 12:00 PM GMT
Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA requesting modification of liver monitoring for FILSPARI
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2025 9:30 PM GMT
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Janu
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Nov 12, 2024 9:05 PM GMT
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of its previously announced underwritten public offering of 8,984,375 shares of its common stock at a price to the public of $16.0